Social News
Written by: Zheng Cuibi
2020-12-25 22:13
Last update date: 2020-12-25 22:14
The new crown pneumonia epidemic continues. Yuan Guoyong, Chair Professor of the Department of Microbiology of the University of Hong Kong, published an article in the newspaper today (25th) to compare three vaccines that the Hong Kong government intends to purchase.
In the evening, he said on the TV program "Free Wind Free Phone" that Kexing's vaccine does not need to be stored at a low temperature. It is convenient for private doctors to bring the vaccine to the home to vaccinate the elderly, and the side effects are not high and are more suitable for the elderly.
However, the protection time of this vaccine may not be long, and it may require injection every two to three years.
As for the vaccines of Fosun Pharma and BioNTech, they are more suitable for medical staff.
He also revealed that the fourth vaccine that the Hong Kong government intends to purchase is a "recombinant protein vaccine" and has just entered the third phase of clinical research.
Yuan Guoyong said that Kexing's vaccine does not need to be stored at low temperature, so that private doctors can bring the vaccine to the home to vaccinate the elderly.
(Kevin Frayer/Getty Images)
Kexing vaccine lacks "lymphocyte-mediated protection"
Turkey today announced the preliminary data of the third phase of the local clinical test of Kexing. According to the data of more than 1,300 people, the protection effect is 91.25%.
When asked about the test data of more than 1,300 people, Yuan Guoyong said that it can be analyzed based on all the data, including the age distribution of testers, various reactions after vaccination, and whether all infections can be found through nucleic acid testing.者 etc.
He believes that the protection rate of Kexing vaccine must be more than 50%, and there is a high chance that it will be higher than 90%.
However, Yuan Guoyong pointed out that Kexing vaccine can only stimulate neutralizing antibodies and lacks "lymphocyte-mediated protection". I believe its protective ability can only be maintained for a short period of time. "It is possible that the vaccine will be used again in two or three years." Not a big problem, the flu vaccine is also injected every year.
Yuan Guoyong said that Kexing vaccine is suitable for the elderly in the hospital.
(Profile picture/Photo by Zhang Haowei)
Fever caused by vaccine can cause cerebrovascular complications
Yuan said that Kexing vaccine is suitable for elderly people in hospitals because it has fewer side effects and the fever rate is 3.3%. Compared with BioNTech's vaccine, the probability of fever is 14.2%.
He pointed out that if the elderly have a high fever, it may cause cerebrovascular complications, vascular diseases, and heart problems, so Kexing's vaccine is more suitable for them.
In addition, Kexing vaccine can be stored for a long time in the refrigerator at 4 degrees Celsius, which is convenient for private doctors to bring the vaccine to the home to vaccinate the elderly. He said that by then, doctors can bring first aid equipment, medications for allergic reactions, and epinephrine syringes to the hospital.
Yuan Guoyong believes that if medical staff have no history of allergies, they should also receive the BioNTech vaccine.
(BioNTech twitter picture)
Refers to medical care suitable for injection of BioNTech vaccine
As for the BioNTech vaccine, it needs to be stored at ultra-low temperature, and medical staff lack experience in injecting such vaccines. It is safer to vaccinate citizens in government vaccination centers and hospitals. Prove that there is no acute allergic reaction to polyethylene glycol (PEG) and get vaccinated first.” Medical staff who also belong to the high-risk group should also receive the BioNTech vaccine if they have no history of allergies.
He pointed out that the current release of the third phase of Kexing's data is delayed. The arrival time of the two vaccines may be similar. He described it as the "best case" because there can be two vaccines at the same time.
▼Vaccination experts answer nine questions▼
+3
+3
+3
AstraZeneca study went wrong, 2 people have serious complications
As for the vaccine of AstraZeneca AstraZeneca, Yuan pointed out that the drug company had mistaken the dose in the third phase of the study. The first dose was half of the original dose, but instead it had a higher protection rate. "Because there was a mistake. Hey, our scientists are so careful. If we don’t do the third phase many times, we will have no confidence to fight.” And in the study, two people developed transverse myelitis, which he described as a serious complication.” You don’t have the right way to go", so you should observe for a while before making a decision.
He also revealed that the fourth vaccine that the Hong Kong government intends to purchase is a "recombinant protein vaccine" and has just entered the third phase of clinical research. The Hong Kong government has not formally contracted with pharmaceutical manufacturers, but it is believed that they will all be ordered.
New Coronary Pneumonia | Newly-made vaccine "prevention of infection" rate is not high, experts expect to be unable to travel after vaccination
New crown vaccine | Yuan Guoyong's team deconstructed the effectiveness of 3 vaccines, it is difficult to prevent asymptomatic infection
[New Coronary Pneumonia] Many Latin American Countries Start Vaccinations, Mexican Nurses Become the First Person in the Continent
Argentine ambassador to China rumored to have been replaced due to ineffective negotiation of China's new crown pneumonia vaccine
01News
New crown pneumonia vaccine new crown vaccine vaccination
